glucagon · Xeris · NDA 212097
Gvoke Hypopen
Earliest generic entry, as listed · earliest of 2 marketed strengths
22 Apr 2036
Blocked by patent: US 11590205, US 9649364.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11590205 | product, use U-2742 | 22 Apr 2036 |
| US 9649364 | product, use U-2742 | 22 Apr 2036 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212097 · 003 · RLD | solution, subcutaneous | 0.5MG/0.1ML (0.5MG/0.1ML) | 22 Apr 2036 |
| 212097 · 004 · RLD | solution, subcutaneous | 1MG/0.2ML (1MG/0.2ML) | 22 Apr 2036 |